Click here to sign in with or
by Zhang Nannan, Chinese Academy of Sciences
Cancer immunotherapy is a treatment modality against tumor growth and metastasis via stimulating host immune responses. Phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is a less invasive treatment compared to chemotherapy. To be specific, PDT and PTT-induced immunogenic cell death can release tumor-associated antigens and damage-associated molecular patterns, stimulating an immune response.
Photo-immunotherapy, the combination of phototherapy and immunotherapy, can effectively enhance treatment effectiveness compared with a single treatment modality. Up to now, the multifunctional photo-immune system is still in its infancy. Hence, the development of a multifunctional and safe photo-immunotherapy system for efficient tumor treatment is urgently needed.
Dong Wenfei's group from the Suzhou Institute of Biomedical Engineering and Technology (SIBET) of the Chinese Academy of Sciences has recently developed a multifunctional nanoplatform based on mesoporous hexagonal core-shell zinc porphyrin-silica nanoparticles (MPSNs) loaded with R837 (a toll-like receptor-7 agonist), which can be used to integrate PDT, PTT, and tumor-specific immunotherapy for breast cancer.
According to the researchers, MPSNs with zinc phosphide (ZnP) as the core and a mesoporous silica framework as the shell could effectively generate singlet oxygen and convert photons to heat with a single light source.
Meanwhile, the mesoporous structure of the silica shell can facilitate efficient R837 loading. Consequently, the therapeutic strategy based on MPSNs@R837 not only eradicated primary tumors via phototherapy modalities (PDT and PTT), but also effectively inhibited distant metastasis due to the strong immune response triggered by the two-way mechanistic interaction.
This study has been published in Journal of Nanobiotechnology. Explore further Researchers develop near-infrared responsive nanoassemblies for combined breast cancer therapy More information: Juan Yue et al, Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy, Journal of Nanobiotechnology (2022). DOI: 10.1186/s12951-022-01388-8 Provided by Chinese Academy of Sciences Citation: Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy (2022, May 30) retrieved 22 July 2022 from https://phys.org/news/2022-05-light-triggered-multifunctional-nanoplatform-efficient-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
More from Physics Forums | Science Articles, Homework Help, Discussion
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Phys.org in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.
Medical research advances and health news
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.